Promising Early Results from NXP800 Trial in Treating Platinum-Resistant Ovarian Cancer

Preliminary results from a Phase 1b clinical trial of the drug NXP800, developed by Nuvectis Pharma, Inc., have shown promising signs in the treatment of platinum-resistant ARID1a-mutated ovarian cancer, a severe and underserved medical condition with a median life expectancy of around one year. The trial, which holds Fast Track Designation by the FDA, is taking place in the US and UK and has demonstrated a 33% response rate and 100% disease control rate among patients. Notably, a complete response was observed in a non-target tumor, offering hope for the drug's potential efficacy against this aggressive cancer.
Nuvectis Pharma's CEO, Ron Bentsur, expressed optimism regarding the early findings, which include a partial response and stable disease in patients who had undergone previous treatments. The company has also implemented dosing management procedures to mitigate side effects and improve patient outcomes. The study involves patients who have failed at least two systemic chemotherapy treatments, and the drug's safety and preliminary efficacy are being assessed.
NXP800, an oral small molecule GCN2 kinase activator, is also being studied for the treatment of cholangiocarcinoma, for which it has received Orphan Drug Designation from the FDA. Nuvectis Pharma, focusing on developing innovative precision medicines for oncology, is advancing two drug candidates, NXP800 and NXP900, with the latter being a novel SRC/YES1 kinase inhibitor.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!